Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Palandri

Showing results (131-140 of 187) with videos related to

Pageof 19
Sort By:
Blood Advances|April 29, 2026
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 studyHarinder Gill, Abdulraheem Yacoub, Aaron T Gerds, et al.
Hemasphere|December 31, 2025
Health-related quality of life and symptom profile of patients with <i>BCR::ABL1</i>-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational studyGiovanni Caocci, Alessandro Costa, Francesca Palandri, et al.
Ejhaem|August 21, 2023
Incidence of blast phase in myelofibrosis according to anemia severityBarbara Mora, Margherita Maffioli, Elisa Rumi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2023
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve MyelofibrosisJohn Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, et al.
Future Oncology (London, England)|August 11, 2022
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosisClaire N Harrison, Vikas K Gupta, Aaron T Gerds, et al.
Blood|April 23, 2021
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopeniaFrancesca Palandri, Elena Rossi, Daniela Bartoletti, et al.
Hematological Oncology|February 16, 2021
Impact of comorbidities and body mass index on the outcome of polycythemia vera patientsGiulia Benevolo, Elena M Elli, Daniela Bartoletti, et al.
Hematological Oncology|April 16, 2019
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinibFrancesca Palandri, Giuseppe A Palumbo, Elisabetta Abruzzese, et al.
American Journal of Hematology|June 15, 2024
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trialBianca Rocca, Alberto Tosetto, Giovanna Petrucci, et al.
The Lancet. Haematology|December 9, 2022
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMTNicola Polverelli, Juan Carlos Hernández-Boluda, Tomasz Czerw, et al.
Pageof 19

Showing results (131-140 of 187) with videos related to

Sort By:
Pageof 19
Blood Advances|April 29, 2026
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 studyHarinder Gill, Abdulraheem Yacoub, Aaron T Gerds, et al.
Hemasphere|December 31, 2025
Health-related quality of life and symptom profile of patients with <i>BCR::ABL1</i>-negative myeloproliferative neoplasms: Real-world evidence from the GIMEMA-PROPHECY observational studyGiovanni Caocci, Alessandro Costa, Francesca Palandri, et al.
Ejhaem|August 21, 2023
Incidence of blast phase in myelofibrosis according to anemia severityBarbara Mora, Margherita Maffioli, Elisa Rumi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2023
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve MyelofibrosisJohn Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, et al.
Future Oncology (London, England)|August 11, 2022
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosisClaire N Harrison, Vikas K Gupta, Aaron T Gerds, et al.
Blood|April 23, 2021
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopeniaFrancesca Palandri, Elena Rossi, Daniela Bartoletti, et al.
Hematological Oncology|February 16, 2021
Impact of comorbidities and body mass index on the outcome of polycythemia vera patientsGiulia Benevolo, Elena M Elli, Daniela Bartoletti, et al.
Hematological Oncology|April 16, 2019
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinibFrancesca Palandri, Giuseppe A Palumbo, Elisabetta Abruzzese, et al.
American Journal of Hematology|June 15, 2024
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trialBianca Rocca, Alberto Tosetto, Giovanna Petrucci, et al.
The Lancet. Haematology|December 9, 2022
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMTNicola Polverelli, Juan Carlos Hernández-Boluda, Tomasz Czerw, et al.
Pageof 19